Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients

Inclusion Criteria: 1. age = 18 years; 2. Informed consent for participation in the study and for data processing; 3. Molecular diagnosis with Polymerase Chain Reaction (PCR) test of Sars-CoV2 infection; 4. Hospitalization in a specialist ward for Covid-19 patient care (eg., Infectious Diseases, Pulmonology or Internal Medicine); 5. Need for supplemental oxygen in any delivery mode with the exception of invasive mechanical ventilation; 6. PaO2 / FiO2 between 100 and 300 mmHg. 7. Clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or lung ultrasound) of interstitial pneumonia for no more than three days; 8. Serum CRP greater than 5 mg / dL; 9. Interval from onset of SARS-CoV2 infection symptoms to randomization\> 5 days- Exclusion Criteria: 1. Invasive mechanical ventilation; 2. Presence of shock or concomitant organ failure that requires admission to the Intensive Care Unit; 3. Pregnancy or breastfeeding; 4. Severe heart or kidney failure; 5. Known hypersensitivity to methylprednisolone, to dexamethasone or to an exception; 6. Diabetes not compensated according to the doctor's judgment; 7. Other clinical conditions that contraindicate Methylprednisolone and cannot be treated or resolved according to the doctor's judgment; 8. Steroid bolus therapy in the week prior to enrollment for the study; 9. Enrollment in another clinical trial; 10. Patient already randomized in this study-